Status:
UNKNOWN
Metronomic Chemotherapy With Tegafur/Uracil for Head and Neck Squamous Cell Carcinoma
Lead Sponsor:
Mackay Memorial Hospital
Conditions:
Head and Neck Cancer
Eligibility:
All Genders
20+ years
Phase:
PHASE2
Brief Summary
It is the investigators understanding that the combination of clinical trial with laboratory cellular/molecular assay is relevant to the current promising mainstream, the translational research. The d...
Detailed Description
Head and neck squamous cell carcinoma (HNSCC) (excluding nasopharyngeal cancer) accounts for 4% to 5% of the cancer incidence in Taiwan.1 Localized disease is curable by surgery and irradiation. Two-t...
Eligibility Criteria
Inclusion
- Histologically confirmed non-nasopharyngeal head and neck squamous cell carcinoma
- Complete response(CR) to previous treatment
- White blood cell (WBC) count greater than 3,000/mm3 and absolute neutrophil count (ANC) greater than 1,500/mm3, and platelets greater than 50,000/mm3
- Serum bilirubin less than 2 times the upper limit of normal range (ULN)
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST)
- Serum creatinine less than 2.0 times the ULN
- ECOG performance status 0, 1, 2
- Age, 20 years or older
Exclusion
- Other malignancy, with the exception of curatively treated non-melanoma skin cancer or cervical carcinoma in situ prior to commencement of the study
- CR was confirmed more than 6 weeks prior to commencement of the study
- Concurrent treatment which may interfere with evaluation
- Pregnancy or breast feeding
Key Trial Info
Start Date :
December 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2016
Estimated Enrollment :
115 Patients enrolled
Trial Details
Trial ID
NCT00855881
Start Date
December 1 2008
End Date
December 1 2016
Last Update
July 26 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mackay Memorial Hospital
Taipei, Taiwan